SCHEMBL4606566

SCHEMBL4606566

O=C(NN1CCCCC1)C1=NN(c2ccc(Cl)cc2Cl)C(c2sccc2I)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 15/20 0.59
CNR2 P34972 12/20 0.59
CYP2C9 P11712 2/20 0.43
GPR55 Q9Y2T6 2/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ABCC4 O15439 1/20 0.42
MLNR O43193 1/20 0.42
ABCB11 O95342 1/20 0.42
CHRM2 P08172 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
DRD1 P21728 1/20 0.42
TBXA2R P21731 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607624 0.93 CNR1 (0.61) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL4606688 0.90 CNR1 (0.58) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL4606048 0.90 CNR1 (0.58) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL4604746 0.84 CNR1 (0.60) CNR1CNR2CYP2C9GPR55NPSR1
SCHEMBL4605074 0.84 CNR1 (0.57) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL1748614 0.84 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL8470688 0.84 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL674917 0.84 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL4608199 0.84 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL8452745 0.84 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
WO-2007009690-A1 HETEROCYCLYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A (ES) 2007-01-25 WO disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed